Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
International Journal of COPD Mar 21, 2018
Lai CC, et al. - Angiotensin-converting-enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) were compared in terms of impacts on the risk of pneumonia and severe exacerbations in patients with COPD. ARBs vs ACEis were shown to be related to lower rates of pneumonia, severe pneumonia, and mortality in patients with COPD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
